Mersana Therapeutics (MRSN) Scheduled to Post Earnings on Thursday

Mersana Therapeutics (NASDAQ:MRSN) is scheduled to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Mersana Therapeutics to post earnings of ($0.18) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $10.70 million for the quarter, compared to analyst estimates of $22.59 million. Mersana Therapeutics had a negative return on equity of 282.36% and a negative net margin of 465.80%. The firm’s revenue for the quarter was down 27.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.44) earnings per share. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mersana Therapeutics Stock Performance

MRSN opened at $3.53 on Wednesday. Mersana Therapeutics has a 12-month low of $0.80 and a 12-month high of $9.62. The firm has a market capitalization of $427.58 million, a P/E ratio of -2.35 and a beta of 1.61. The stock’s 50 day moving average price is $4.32 and its two-hundred day moving average price is $3.08. The company has a quick ratio of 3.36, a current ratio of 3.36 and a debt-to-equity ratio of 0.63.

Wall Street Analysts Forecast Growth

MRSN has been the subject of several research analyst reports. BTIG Research upgraded shares of Mersana Therapeutics from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Thursday, February 29th. Robert W. Baird lifted their target price on Mersana Therapeutics from $1.00 to $5.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. Guggenheim raised Mersana Therapeutics from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a report on Thursday, February 29th. JPMorgan Chase & Co. raised Mersana Therapeutics from an “underweight” rating to a “neutral” rating and set a $5.00 price objective on the stock in a report on Tuesday, March 19th. Finally, Truist Financial upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research note on Thursday, February 29th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $6.29.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.